The modulation of prostate cancer risk with α-tocopherol

A pilot randomized, controlled clinical trial

Javier Hernández, Samira Syed, Geoffrey Weiss, Gabriel Fernandes, Dendra Von Merveldt, Dean A. Troyer, Joseph W. Basler, Ian M. Thompson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Studies suggest that vitamin E may decrease the risk of prostate cancer. The Prevention Research Veteran Affairs E-vitamin Nutrition Trial is a randomized, double-blind, placebo controlled study designed to assess the effects of vitamin E supplementation on biomarkers associated with prostate cancer risk in peripheral blood and prostate tissue. Materials and Methods: A total of 44 patients with increased prostate specific antigen (PSA) and/or abnormal digital rectal examination on initial evaluation were randomized to receive 400 IU vitamin E (22) vs placebo (22). Serum vitamin E, PSA, dehydroepiandrosterone, testosterone and insulin-like growth factor-1 (IGF-1) were measured in the 2 groups at baseline and then at 3-month intervals. Results are reported in 28 patients (placebo in 14 and vitamin E in 14) who completed the treatment as specified by the protocol. Results: Serum Vitamin E was significantly higher in patients on vitamin E supplementation. α-Tocopherol supplementation did not affect the levels of PSA, serum androgens (testosterone and dehydroepiandrosterone) or (IGF-1). Conclusions: Serum α-tocopherol is increased by oral supplementation of vitamin E. We found that α-tocopherol supplementation has no effect on serum androgens, IGF-1 or PSA. The lack of an effect of vitamin supplementation on PSA avoids any bias in the diagnosis of prostate cancer in vitamin E treated patients. Our results suggest that a decrease in prostate cancer risk with α-tocopherol is likely to occur through a mechanism that is nonhormonal and independent of IGF-1.

Original languageEnglish (US)
Pages (from-to)519-522
Number of pages4
JournalJournal of Urology
Volume174
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Tocopherols
Vitamin E
Prostatic Neoplasms
Randomized Controlled Trials
Prostate-Specific Antigen
Somatomedins
Serum
Dehydroepiandrosterone
Placebos
Androgens
Testosterone
Digital Rectal Examination
Veterans
Vitamins
Prostate
Biomarkers

Keywords

  • α-tocopherol
  • Biological
  • Prostate
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

Hernández, J., Syed, S., Weiss, G., Fernandes, G., Von Merveldt, D., Troyer, D. A., ... Thompson, I. M. (2005). The modulation of prostate cancer risk with α-tocopherol: A pilot randomized, controlled clinical trial. Journal of Urology, 174(2), 519-522. https://doi.org/10.1097/01.ju.0000165151.08560.6a

The modulation of prostate cancer risk with α-tocopherol : A pilot randomized, controlled clinical trial. / Hernández, Javier; Syed, Samira; Weiss, Geoffrey; Fernandes, Gabriel; Von Merveldt, Dendra; Troyer, Dean A.; Basler, Joseph W.; Thompson, Ian M.

In: Journal of Urology, Vol. 174, No. 2, 08.2005, p. 519-522.

Research output: Contribution to journalArticle

Hernández, J, Syed, S, Weiss, G, Fernandes, G, Von Merveldt, D, Troyer, DA, Basler, JW & Thompson, IM 2005, 'The modulation of prostate cancer risk with α-tocopherol: A pilot randomized, controlled clinical trial', Journal of Urology, vol. 174, no. 2, pp. 519-522. https://doi.org/10.1097/01.ju.0000165151.08560.6a
Hernández, Javier ; Syed, Samira ; Weiss, Geoffrey ; Fernandes, Gabriel ; Von Merveldt, Dendra ; Troyer, Dean A. ; Basler, Joseph W. ; Thompson, Ian M. / The modulation of prostate cancer risk with α-tocopherol : A pilot randomized, controlled clinical trial. In: Journal of Urology. 2005 ; Vol. 174, No. 2. pp. 519-522.
@article{55476cf176a54fdc8a2692842792a017,
title = "The modulation of prostate cancer risk with α-tocopherol: A pilot randomized, controlled clinical trial",
abstract = "Purpose: Studies suggest that vitamin E may decrease the risk of prostate cancer. The Prevention Research Veteran Affairs E-vitamin Nutrition Trial is a randomized, double-blind, placebo controlled study designed to assess the effects of vitamin E supplementation on biomarkers associated with prostate cancer risk in peripheral blood and prostate tissue. Materials and Methods: A total of 44 patients with increased prostate specific antigen (PSA) and/or abnormal digital rectal examination on initial evaluation were randomized to receive 400 IU vitamin E (22) vs placebo (22). Serum vitamin E, PSA, dehydroepiandrosterone, testosterone and insulin-like growth factor-1 (IGF-1) were measured in the 2 groups at baseline and then at 3-month intervals. Results are reported in 28 patients (placebo in 14 and vitamin E in 14) who completed the treatment as specified by the protocol. Results: Serum Vitamin E was significantly higher in patients on vitamin E supplementation. α-Tocopherol supplementation did not affect the levels of PSA, serum androgens (testosterone and dehydroepiandrosterone) or (IGF-1). Conclusions: Serum α-tocopherol is increased by oral supplementation of vitamin E. We found that α-tocopherol supplementation has no effect on serum androgens, IGF-1 or PSA. The lack of an effect of vitamin supplementation on PSA avoids any bias in the diagnosis of prostate cancer in vitamin E treated patients. Our results suggest that a decrease in prostate cancer risk with α-tocopherol is likely to occur through a mechanism that is nonhormonal and independent of IGF-1.",
keywords = "α-tocopherol, Biological, Prostate, Prostate-specific antigen, Prostatic neoplasms, Tumor markers",
author = "Javier Hern{\'a}ndez and Samira Syed and Geoffrey Weiss and Gabriel Fernandes and {Von Merveldt}, Dendra and Troyer, {Dean A.} and Basler, {Joseph W.} and Thompson, {Ian M.}",
year = "2005",
month = "8",
doi = "10.1097/01.ju.0000165151.08560.6a",
language = "English (US)",
volume = "174",
pages = "519--522",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The modulation of prostate cancer risk with α-tocopherol

T2 - A pilot randomized, controlled clinical trial

AU - Hernández, Javier

AU - Syed, Samira

AU - Weiss, Geoffrey

AU - Fernandes, Gabriel

AU - Von Merveldt, Dendra

AU - Troyer, Dean A.

AU - Basler, Joseph W.

AU - Thompson, Ian M.

PY - 2005/8

Y1 - 2005/8

N2 - Purpose: Studies suggest that vitamin E may decrease the risk of prostate cancer. The Prevention Research Veteran Affairs E-vitamin Nutrition Trial is a randomized, double-blind, placebo controlled study designed to assess the effects of vitamin E supplementation on biomarkers associated with prostate cancer risk in peripheral blood and prostate tissue. Materials and Methods: A total of 44 patients with increased prostate specific antigen (PSA) and/or abnormal digital rectal examination on initial evaluation were randomized to receive 400 IU vitamin E (22) vs placebo (22). Serum vitamin E, PSA, dehydroepiandrosterone, testosterone and insulin-like growth factor-1 (IGF-1) were measured in the 2 groups at baseline and then at 3-month intervals. Results are reported in 28 patients (placebo in 14 and vitamin E in 14) who completed the treatment as specified by the protocol. Results: Serum Vitamin E was significantly higher in patients on vitamin E supplementation. α-Tocopherol supplementation did not affect the levels of PSA, serum androgens (testosterone and dehydroepiandrosterone) or (IGF-1). Conclusions: Serum α-tocopherol is increased by oral supplementation of vitamin E. We found that α-tocopherol supplementation has no effect on serum androgens, IGF-1 or PSA. The lack of an effect of vitamin supplementation on PSA avoids any bias in the diagnosis of prostate cancer in vitamin E treated patients. Our results suggest that a decrease in prostate cancer risk with α-tocopherol is likely to occur through a mechanism that is nonhormonal and independent of IGF-1.

AB - Purpose: Studies suggest that vitamin E may decrease the risk of prostate cancer. The Prevention Research Veteran Affairs E-vitamin Nutrition Trial is a randomized, double-blind, placebo controlled study designed to assess the effects of vitamin E supplementation on biomarkers associated with prostate cancer risk in peripheral blood and prostate tissue. Materials and Methods: A total of 44 patients with increased prostate specific antigen (PSA) and/or abnormal digital rectal examination on initial evaluation were randomized to receive 400 IU vitamin E (22) vs placebo (22). Serum vitamin E, PSA, dehydroepiandrosterone, testosterone and insulin-like growth factor-1 (IGF-1) were measured in the 2 groups at baseline and then at 3-month intervals. Results are reported in 28 patients (placebo in 14 and vitamin E in 14) who completed the treatment as specified by the protocol. Results: Serum Vitamin E was significantly higher in patients on vitamin E supplementation. α-Tocopherol supplementation did not affect the levels of PSA, serum androgens (testosterone and dehydroepiandrosterone) or (IGF-1). Conclusions: Serum α-tocopherol is increased by oral supplementation of vitamin E. We found that α-tocopherol supplementation has no effect on serum androgens, IGF-1 or PSA. The lack of an effect of vitamin supplementation on PSA avoids any bias in the diagnosis of prostate cancer in vitamin E treated patients. Our results suggest that a decrease in prostate cancer risk with α-tocopherol is likely to occur through a mechanism that is nonhormonal and independent of IGF-1.

KW - α-tocopherol

KW - Biological

KW - Prostate

KW - Prostate-specific antigen

KW - Prostatic neoplasms

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=22144492228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144492228&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000165151.08560.6a

DO - 10.1097/01.ju.0000165151.08560.6a

M3 - Article

VL - 174

SP - 519

EP - 522

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -